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Abstract Diabetes mellitus (DM) is a lifelong progressive
disease with high morbidity and mortality worldwide.
Whereas cardiovascular complications are well-known for
DM, increasing evidence indicates that diabetics are
predisposed to cancer. Understanding of molecular patho-
mechanisms of cancer in DM is of great importance.
Dysregulation of glucose/insulin homeostasis leads to
increased production of Reactive Oxygen/Nitrogen Species
(ROS/RNS) and consequent damage to chromosomal/
mitochondrial DNA, a frequent finding in DM. Long-term
accumulation of modified/damaged DNA is well-
acknowledged as triggering cancer. DNA-repair is a highly
energy consuming process provoking increased mitochon-
drial activity. Particularly dangerous is a provoked activity
of damaged mitochondria leading to a “vicious circle”
lowering energy supply and potentiating ROS/RNS pro-
duction. Mitochondrial dysfunction may be implicated in
pathomechanisms of diabetes-related cancer. High risk for
infectious disorders and induced viral proto-oncogenic
activity may further contribute to cancer provocation. Much
attention should be focused on preventive measures in
diabetic healthcare, in order to restrict severe diabetes-
related complications.
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Diabetes mellitus as general risk factor for cancer
Diabetes mellitus (DM) is a group of metabolic disorders,
mainly characterized by impaired glucose metabolism and
consequent hyperglycemia as the common feature. Whereas
cardiovascular complications are well described for DM [1],
it is a relatively new consideration that diabetic patients are
highly predisposed to cancer. In spite of some ethnic-,
gender-, and age-specific differences, significantly increased
risk of liver, pancreas, bladder and digestive tract cancer
types is generally recognized for DM-patients (Fig. 1).
Many population studies indicate an increased risk for
almost all kinds of cancer in DM with particular ethnic- as
well as gender-dependent preferences (Fig. 2).
With respect to single DM-types, population studies
have been carried out in different countries showing
geographic particularities in cancer incidence. Thus, long-
term monitoring of a cancer-specific incidence in the
subpopulation of type 1 diabetics was performed in Sweden
during 1965–1999 [8]. It is noteworthy that particular risk
in childhood was demonstrated for endometrial, buccal-
cavity, bladder as well as cervix cancer types (Fig. 3). In
adulthood, the highest risk has been registered for cancer of
stomach, endometrium, cervix, and bladder.
Similar studies carried out for type 2 diabetes demon-
strate liver, pancreas and bladder cancer to be the leading
types (Fig. 4).
Cancer-related mortality in diabetics
According to the current worldwide statistics, every 10 s one
patient dies due to DM-related consequences: DM is
currently the fourth leading cause of death [10]. Furthermore,
accumulating data demonstrate that, once appeared, cancer
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outcomes have worse prognosis for diabetics compared to
non-diabetic oncologic patients (Fig. 5).
This general figures are well-supported by data collected
in USA to treatment of single cancer types as represented in
Fig. 6. These data clearly indicate less success in treatment
of cancer for DM-patients.
The hindered treatment of oncologic diseases in diabetes
care is, however, not the only reason of significantly
increased cancer-related mortality of diabetics. Recent
studies indicate that diabetics are generally predisposed to
cancer development [2–9, 11–22]. Here we overview
subcellular and molecular mechanisms that can contribute
to cancer-provocation in diabetics.
Subcellular and molecular mechanisms
in DM-predisposition to cancer
Mitochondrial dysfunction
Increased oxidative stress has been implicated in molecular
pathomechanisms of DM and majority of chronic diseases
developed secondary to diabetes [23–25]. Several studies
demonstrated the excessive production of ROS to be the
common feature of both diabetes types [10, 22, 26–28].
Disturbed glucose/insulin homeostasis initiates overall
cellular stress leading to ir/reversible damage to subcellular
structures [28, 29].
Oxidative damage to DNA is well documented for cells
isolated from diabetics [30]. These findings indicate an
imbalance between the increased production of ROS and
decreased DNA-repair capacity. Depending on a quality of
cell-cycle controlling machinery, this imbalance can lead
either to extensive apoptotic cell lost or proliferation of
damaged cells [31]. Whereas the first process causes mainly
tissue-degeneration, the latter predisposes to cancer devel-
opment. Both degenerative alterations in damaged organs
and predisposition to cancer have been reported for DM-
patients.
Extensive damage to DNA as well as mutations has been
demonstrated also for mitochondria in DM-patients [28, 32,
33]. Mitochondrial genetic background as well as mito-
chondrial stress-response is considered as an important
contributor in predisposition to cancer in diabetics [32, 34,
35]. Electron transfer chain (ETC) is the main energy
source essential for performance of all cellular functions.
Particularly, DNA-repair is a highly energy-consuming
machinery, the efficiency of which obligatory depends on
the quality of mitochondria. Mitochondrial DNA variations
may affect a highly sensitive balance between ETC-
efficiency and production of ROS in favor of the latter
increasing, therefore, mutagenic effects of ROS and
decreasing energy production. This is so called “vicious
circle” resulting in mitochondrial dysfunction (Fig. 7). As
for mitochondrial protein repertoire, both quantitative and























Fig. 1 General predisposition of diabetics to single cancer types: breast












































Fig. 2 Population studies in
Japan as an example of cancer
predisposition of diabetics in
years 1990–2003 [7]
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of the ETC-complex I) have been shown to contribute to
the “vicious circle” resulting in premature aging and plenty
of pathologies including neurodegeneration and cancer
[36]. In diabetics, the mitochondrial “vicious circle” has
been implicated specifically in individual predisposition to
breast cancer [37].
Concept of viral etiology in DM-provoked cancer
Patients with diabetic history are at increased risk of
infection [38–40]. There is a growing body of evidence
for compromised immune response in this patient cohort as
a consequence of metabolic syndrome [41–43]. This
imbalance can lead to highly increased incidence of viral
infection potentiating cancer risk in diabetics [43–46].
Currently it is already well-acknowledged that more than
15 % of viral infections are able to cause cancer in humans
[47]. Thus, human papillomavirus (HPV) infection is
attributed to 80 % of all human cancers and was proposed
to play a central role in molecular pathomechanisms of
breast cancer [48–50]. Integration of viral particles in
human genome frequently results in activation of several
proto-oncogenes, which in turn trigger tumorigenic mech-
anisms in affected cells [22, 48, 51–53]. Thus, a viral
activation of proto-oncogene c-MYC is well described in
literature [48]. Thereby, a targeted integration of viral
particles in human genome plays the crucial role for
consequent cancer development [47, 48, 54]. In this
context, HPV demonstrates clear preference for its integra-
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Fig. 3 Specific cancer inci-
dence with respect to age in
Swedish diabetics type 1 regis-
tered in years 1965–1999 [8]
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coding sequences [48]. Once activated, c-MYC protein
suppresses the cell-cycle controlling activity of P53, and
allows, therefore, the development of new tumorigenic
phenotype of transformed human cells [22, 48, 52]. In
consensus, the activated synthesis of viral proteins E6, E7,
E1 and E2 has been shown to be involved in cancer-related
cell transformation [48, 55]. Most relevant mechanisms for
viral etiology of cancer predisposition, particularly, in DM-
pathology are summarized in Fig. 8.
The overall concept of cancer-predisposition in diabetics
Taking together the above given facts, we conclude that
diabetics may be highly predisposed to cancer development
specifically due to following contributors [57]:
– strong stress factors (excessive metabolic alterations,
disturbed glucose/insulin homeostasis, hormonal de-
regulation, insufficient detoxification) with consequent-
ly excessive production of ROS
– mitochondrial dysfunction with consequent low energy
production, insufficient repair capacity and accumulat-
ing damage to both chromosomal and mitochondrial
DNA
– high risk for infectious disorders with consequently
induced viral proto-oncogenic activity as well as
activity of particular pathogenic bacterial forms such
as Helicobacter pylori.
Adequacy of stress response, repair capacity as well as
immune defence are highly individual for each patient and
strongly depend on risk factors such as genetic background,
age, environmental factors, nutrition, body culture, life
style, etc. (Fig. 9). Thus, varying breast cancer risk in
different ethnic and social groups is well documented [16,
58–60]. Breast fat deposits and distribution increase risk for
breast cancer in female and even in male patients [16, 61–
65]. In contrast, breast cancer development is significantly
reduced in people with regular physical activity [66].
Alcohol abuse and tobacco consumption are further con-
tributors which remarkably increase risk of cancer devel-
opment [17, 20, 67–71].
Outlook
Current biotechnology possesses sufficient power to
estimate the severity of damage to subcellular structures,
individual stress reactions and repair capacity. For
example, by stress proteome profiling in peripheral
leukocytes and blood plasma, individual stress reactions
can be well estimated. Advanced predictive diagnostic
approaches are currently close to clinical application
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Fig. 5 Mortality by cancer in diabetic versus non-diabetic patients


































Fig. 6 Increased mortality of
diabetics versus non-diabetics
for single cancer types as docu-
mented for patients treated in
USA in years 1982–1998 [12]
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predisposition to severe complications in diabetics [34,
82–84].
Much attention should be focused on preventive meas-
ures in diabetic healthcare, in order to restrict or even avoid
severe secondary complications, such as cancer [85].
Potential groups of risk should be informed about good
lifestyle choices. Nowadays, it is increasingly clear that a
well-balanced individually created diet is considered as an
effective preventive measure and treatment of majority of
chronic complications in diabetics [86–88].
Fig. 7 Mitochondrial “vicious
circle” causes a dangerous im-
balance between highly in-
creased production of ROS on
one side and low energy pro-
duction on the other side. High-
ly increased damage to chrDNA
and mtDNA, remarkably de-
crease repair capacity as well as
compromise cell-cycle control
are direct consequences of
stress-provoked mitochondrial
dysfunction [22, 26, 28, 33, 36]
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Fig. 8 Clue to viral etiology in DM-provoked cancer: “vicious circle” is the particularity of metabolic syndrome with high risk of cancer
development [22, 26, 28, 33, 36, 38–45, 51–56]
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